Loading…
Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009
BACKGROUND: Completion of the human papillomavirus (HPV) vaccine in a large percentage of young females is an important goal to prevent anogenital cancers associated with HPV. The current study examined whether the percentage of insured women who complete the vaccine series has changed across time,...
Saved in:
Published in: | Cancer 2012-11, Vol.118 (22), p.5623-5629 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c3958-7f4d224e2c15f61bac72c809bd2c6f7427f99d7fc4b0529bc66c04f2794276303 |
---|---|
cites | cdi_FETCH-LOGICAL-c3958-7f4d224e2c15f61bac72c809bd2c6f7427f99d7fc4b0529bc66c04f2794276303 |
container_end_page | 5629 |
container_issue | 22 |
container_start_page | 5623 |
container_title | Cancer |
container_volume | 118 |
creator | Hirth, Jacqueline M. Tan, Alai Wilkinson, Gregg S. Berenson, Abbey B. |
description | BACKGROUND:
Completion of the human papillomavirus (HPV) vaccine in a large percentage of young females is an important goal to prevent anogenital cancers associated with HPV. The current study examined whether the percentage of insured women who complete the vaccine series has changed across time, and how provider type and age at initiation affects rates of completion.
METHODS:
This retrospective cohort study used administrative data from a private insurance company. The study included 271,976 females in whom the HPV vaccine series was initiated and who had been continuously enrolled in their respective insurance plan for 365 days after vaccine initiation. Multivariate logistic regression was used to determine the odds of completing the vaccine series within 365 days after initiation.
RESULTS:
Females aged 13 years to 18 years, 19 years to 26 years, and ≥ 27 years were found to be less likely than those ages 9 years to 12 years to complete their HPV vaccine series. Obstetricians/gynecologists were more likely to administer vaccines to completers than pediatricians, whereas clinics, nurses, family care practitioners, and specialists were less likely to administer initial vaccines to completers compared with pediatricians. The results of the current study also found that females aged 9 years to 12 years and 13 years to 18 years had lower odds of completing the HPV vaccine series for each subsequent year compared with those aged 19 years to 26 years and ≥ 27 years.
CONCLUSIONS:
Among insured females in the United States, the percentage of females who complete the HPV vaccine series is dropping over time, especially among younger females, who are specifically targeted to receive the vaccine. Physicians need to stress the importance of completing all 3 vaccinations to their patients. Cancer 2012. © 2012 American Cancer Society.
The percentage of insured females who complete the human papillomavirus (HPV) vaccine series is declining, particularly among females aged 9 years to 12 years and 13 years to 18 years. Physicians should increase their efforts to encourage their patients to complete the HPV vaccine series. |
doi_str_mv | 10.1002/cncr.27598 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1125249381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1125249381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3958-7f4d224e2c15f61bac72c809bd2c6f7427f99d7fc4b0529bc66c04f2794276303</originalsourceid><addsrcrecordid>eNp90M9rFTEQB_BQlPa19tI_QHIRpLA1mc2PzVEWtYWiIArelmx2YiPZ7Jq8bel_7z7fq715ymTmwwx8Cbng7IozBu9ccvkKtDTNEdlwZnTFuIAXZMMYayop6h8n5LSUX-tXg6yPyQmAFEI1fENsO41zxG2YEp083d4hvVtGm-hs5xDjNNr7kJdC761zISEtmAMWascp_aQhlSXjQD2ONq7dHrcPiIkCY4raNOwK84q89DYWPD-8Z-T7xw_f2uvq9sunm_b9beVqI5tKezEACATHpVe8t06Da5jpB3DKawHaGzNo70TPJJjeKeWY8KDNOlI1q8_I2_3eOU-_FyzbbgzFYYw24bSUjnOQIEzd8JVe7qnLUykZfTfnMNr82HHW7SLtdpF2fyNd8evD3qUfcfhHnzJcwZsDsMXZ6LNNLpRnp6Qyqtar43v3ECI-_udk135uv-6P_wFHJ4z_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1125249381</pqid></control><display><type>article</type><title>Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009</title><source>Electronic Journals Library</source><source>Wiley-Blackwell Read & Publish Collection</source><creator>Hirth, Jacqueline M. ; Tan, Alai ; Wilkinson, Gregg S. ; Berenson, Abbey B.</creator><creatorcontrib>Hirth, Jacqueline M. ; Tan, Alai ; Wilkinson, Gregg S. ; Berenson, Abbey B.</creatorcontrib><description>BACKGROUND:
Completion of the human papillomavirus (HPV) vaccine in a large percentage of young females is an important goal to prevent anogenital cancers associated with HPV. The current study examined whether the percentage of insured women who complete the vaccine series has changed across time, and how provider type and age at initiation affects rates of completion.
METHODS:
This retrospective cohort study used administrative data from a private insurance company. The study included 271,976 females in whom the HPV vaccine series was initiated and who had been continuously enrolled in their respective insurance plan for 365 days after vaccine initiation. Multivariate logistic regression was used to determine the odds of completing the vaccine series within 365 days after initiation.
RESULTS:
Females aged 13 years to 18 years, 19 years to 26 years, and ≥ 27 years were found to be less likely than those ages 9 years to 12 years to complete their HPV vaccine series. Obstetricians/gynecologists were more likely to administer vaccines to completers than pediatricians, whereas clinics, nurses, family care practitioners, and specialists were less likely to administer initial vaccines to completers compared with pediatricians. The results of the current study also found that females aged 9 years to 12 years and 13 years to 18 years had lower odds of completing the HPV vaccine series for each subsequent year compared with those aged 19 years to 26 years and ≥ 27 years.
CONCLUSIONS:
Among insured females in the United States, the percentage of females who complete the HPV vaccine series is dropping over time, especially among younger females, who are specifically targeted to receive the vaccine. Physicians need to stress the importance of completing all 3 vaccinations to their patients. Cancer 2012. © 2012 American Cancer Society.
The percentage of insured females who complete the human papillomavirus (HPV) vaccine series is declining, particularly among females aged 9 years to 12 years and 13 years to 18 years. Physicians should increase their efforts to encourage their patients to complete the HPV vaccine series.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.27598</identifier><identifier>PMID: 22544681</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adolescent ; Adult ; Alphapapillomavirus ; Biological and medical sciences ; Child ; Cohort Studies ; Female ; Genital Neoplasms, Female - prevention & control ; Genital Neoplasms, Female - virology ; human papillomavirus ; human papillomavirus (HPV) vaccines ; human papillomavirus vaccine L1 ; Humans ; Infectious diseases ; Insurance, Health ; Medical sciences ; Papillomavirus Infections - prevention & control ; papillomavirus vaccines ; Papillomavirus Vaccines - administration & dosage ; Patient Compliance ; Retrospective Studies ; Tumors ; type 6, 11, 16, 18 ; Vaccination ; Viral diseases ; Young Adult</subject><ispartof>Cancer, 2012-11, Vol.118 (22), p.5623-5629</ispartof><rights>Copyright © 2012 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2012 American Cancer Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3958-7f4d224e2c15f61bac72c809bd2c6f7427f99d7fc4b0529bc66c04f2794276303</citedby><cites>FETCH-LOGICAL-c3958-7f4d224e2c15f61bac72c809bd2c6f7427f99d7fc4b0529bc66c04f2794276303</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26569637$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22544681$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hirth, Jacqueline M.</creatorcontrib><creatorcontrib>Tan, Alai</creatorcontrib><creatorcontrib>Wilkinson, Gregg S.</creatorcontrib><creatorcontrib>Berenson, Abbey B.</creatorcontrib><title>Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND:
Completion of the human papillomavirus (HPV) vaccine in a large percentage of young females is an important goal to prevent anogenital cancers associated with HPV. The current study examined whether the percentage of insured women who complete the vaccine series has changed across time, and how provider type and age at initiation affects rates of completion.
METHODS:
This retrospective cohort study used administrative data from a private insurance company. The study included 271,976 females in whom the HPV vaccine series was initiated and who had been continuously enrolled in their respective insurance plan for 365 days after vaccine initiation. Multivariate logistic regression was used to determine the odds of completing the vaccine series within 365 days after initiation.
RESULTS:
Females aged 13 years to 18 years, 19 years to 26 years, and ≥ 27 years were found to be less likely than those ages 9 years to 12 years to complete their HPV vaccine series. Obstetricians/gynecologists were more likely to administer vaccines to completers than pediatricians, whereas clinics, nurses, family care practitioners, and specialists were less likely to administer initial vaccines to completers compared with pediatricians. The results of the current study also found that females aged 9 years to 12 years and 13 years to 18 years had lower odds of completing the HPV vaccine series for each subsequent year compared with those aged 19 years to 26 years and ≥ 27 years.
CONCLUSIONS:
Among insured females in the United States, the percentage of females who complete the HPV vaccine series is dropping over time, especially among younger females, who are specifically targeted to receive the vaccine. Physicians need to stress the importance of completing all 3 vaccinations to their patients. Cancer 2012. © 2012 American Cancer Society.
The percentage of insured females who complete the human papillomavirus (HPV) vaccine series is declining, particularly among females aged 9 years to 12 years and 13 years to 18 years. Physicians should increase their efforts to encourage their patients to complete the HPV vaccine series.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Alphapapillomavirus</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Genital Neoplasms, Female - prevention & control</subject><subject>Genital Neoplasms, Female - virology</subject><subject>human papillomavirus</subject><subject>human papillomavirus (HPV) vaccines</subject><subject>human papillomavirus vaccine L1</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Insurance, Health</subject><subject>Medical sciences</subject><subject>Papillomavirus Infections - prevention & control</subject><subject>papillomavirus vaccines</subject><subject>Papillomavirus Vaccines - administration & dosage</subject><subject>Patient Compliance</subject><subject>Retrospective Studies</subject><subject>Tumors</subject><subject>type 6, 11, 16, 18</subject><subject>Vaccination</subject><subject>Viral diseases</subject><subject>Young Adult</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNp90M9rFTEQB_BQlPa19tI_QHIRpLA1mc2PzVEWtYWiIArelmx2YiPZ7Jq8bel_7z7fq715ymTmwwx8Cbng7IozBu9ccvkKtDTNEdlwZnTFuIAXZMMYayop6h8n5LSUX-tXg6yPyQmAFEI1fENsO41zxG2YEp083d4hvVtGm-hs5xDjNNr7kJdC761zISEtmAMWascp_aQhlSXjQD2ONq7dHrcPiIkCY4raNOwK84q89DYWPD-8Z-T7xw_f2uvq9sunm_b9beVqI5tKezEACATHpVe8t06Da5jpB3DKawHaGzNo70TPJJjeKeWY8KDNOlI1q8_I2_3eOU-_FyzbbgzFYYw24bSUjnOQIEzd8JVe7qnLUykZfTfnMNr82HHW7SLtdpF2fyNd8evD3qUfcfhHnzJcwZsDsMXZ6LNNLpRnp6Qyqtar43v3ECI-_udk135uv-6P_wFHJ4z_</recordid><startdate>20121115</startdate><enddate>20121115</enddate><creator>Hirth, Jacqueline M.</creator><creator>Tan, Alai</creator><creator>Wilkinson, Gregg S.</creator><creator>Berenson, Abbey B.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20121115</creationdate><title>Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009</title><author>Hirth, Jacqueline M. ; Tan, Alai ; Wilkinson, Gregg S. ; Berenson, Abbey B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3958-7f4d224e2c15f61bac72c809bd2c6f7427f99d7fc4b0529bc66c04f2794276303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Alphapapillomavirus</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Genital Neoplasms, Female - prevention & control</topic><topic>Genital Neoplasms, Female - virology</topic><topic>human papillomavirus</topic><topic>human papillomavirus (HPV) vaccines</topic><topic>human papillomavirus vaccine L1</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Insurance, Health</topic><topic>Medical sciences</topic><topic>Papillomavirus Infections - prevention & control</topic><topic>papillomavirus vaccines</topic><topic>Papillomavirus Vaccines - administration & dosage</topic><topic>Patient Compliance</topic><topic>Retrospective Studies</topic><topic>Tumors</topic><topic>type 6, 11, 16, 18</topic><topic>Vaccination</topic><topic>Viral diseases</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hirth, Jacqueline M.</creatorcontrib><creatorcontrib>Tan, Alai</creatorcontrib><creatorcontrib>Wilkinson, Gregg S.</creatorcontrib><creatorcontrib>Berenson, Abbey B.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hirth, Jacqueline M.</au><au>Tan, Alai</au><au>Wilkinson, Gregg S.</au><au>Berenson, Abbey B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2012-11-15</date><risdate>2012</risdate><volume>118</volume><issue>22</issue><spage>5623</spage><epage>5629</epage><pages>5623-5629</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND:
Completion of the human papillomavirus (HPV) vaccine in a large percentage of young females is an important goal to prevent anogenital cancers associated with HPV. The current study examined whether the percentage of insured women who complete the vaccine series has changed across time, and how provider type and age at initiation affects rates of completion.
METHODS:
This retrospective cohort study used administrative data from a private insurance company. The study included 271,976 females in whom the HPV vaccine series was initiated and who had been continuously enrolled in their respective insurance plan for 365 days after vaccine initiation. Multivariate logistic regression was used to determine the odds of completing the vaccine series within 365 days after initiation.
RESULTS:
Females aged 13 years to 18 years, 19 years to 26 years, and ≥ 27 years were found to be less likely than those ages 9 years to 12 years to complete their HPV vaccine series. Obstetricians/gynecologists were more likely to administer vaccines to completers than pediatricians, whereas clinics, nurses, family care practitioners, and specialists were less likely to administer initial vaccines to completers compared with pediatricians. The results of the current study also found that females aged 9 years to 12 years and 13 years to 18 years had lower odds of completing the HPV vaccine series for each subsequent year compared with those aged 19 years to 26 years and ≥ 27 years.
CONCLUSIONS:
Among insured females in the United States, the percentage of females who complete the HPV vaccine series is dropping over time, especially among younger females, who are specifically targeted to receive the vaccine. Physicians need to stress the importance of completing all 3 vaccinations to their patients. Cancer 2012. © 2012 American Cancer Society.
The percentage of insured females who complete the human papillomavirus (HPV) vaccine series is declining, particularly among females aged 9 years to 12 years and 13 years to 18 years. Physicians should increase their efforts to encourage their patients to complete the HPV vaccine series.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>22544681</pmid><doi>10.1002/cncr.27598</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-543X |
ispartof | Cancer, 2012-11, Vol.118 (22), p.5623-5629 |
issn | 0008-543X 1097-0142 |
language | eng |
recordid | cdi_proquest_miscellaneous_1125249381 |
source | Electronic Journals Library; Wiley-Blackwell Read & Publish Collection |
subjects | Adolescent Adult Alphapapillomavirus Biological and medical sciences Child Cohort Studies Female Genital Neoplasms, Female - prevention & control Genital Neoplasms, Female - virology human papillomavirus human papillomavirus (HPV) vaccines human papillomavirus vaccine L1 Humans Infectious diseases Insurance, Health Medical sciences Papillomavirus Infections - prevention & control papillomavirus vaccines Papillomavirus Vaccines - administration & dosage Patient Compliance Retrospective Studies Tumors type 6, 11, 16, 18 Vaccination Viral diseases Young Adult |
title | Completion of the human papillomavirus vaccine series among insured females between 2006 and 2009 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T02%3A50%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Completion%20of%20the%20human%20papillomavirus%20vaccine%20series%20among%20insured%20females%20between%202006%20and%202009&rft.jtitle=Cancer&rft.au=Hirth,%20Jacqueline%20M.&rft.date=2012-11-15&rft.volume=118&rft.issue=22&rft.spage=5623&rft.epage=5629&rft.pages=5623-5629&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.27598&rft_dat=%3Cproquest_cross%3E1125249381%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3958-7f4d224e2c15f61bac72c809bd2c6f7427f99d7fc4b0529bc66c04f2794276303%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1125249381&rft_id=info:pmid/22544681&rfr_iscdi=true |